Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma

Yu Yun Shao, Zhong Zhe Lin, Chiun Hsu, Kuan Der Lee, Chi Huang Hsiao, Yen Shen Lu, Chien Chung Huang, Yin Chun Shen, Chih Hung Hsu, Ann Lii Cheng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objectives: Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC). We initiated a phase II study to determine the safety and efficacy of adding metronomic chemotherapy to thalidomide as first-line therapy. Methods: This open- labeled, single-arm, multicentered, investigator-initiated study enrolled patients with treatment-naïve advanced HCC not amenable to locoregional therapies. Treatment included oral thalidomide (100 mg twice daily) and tegafur/uracil [125 mg/m2 (based on tegafur) twice daily]. Tumor assessment was performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Pretreatment plasma levels of angiogenesis factors were correlated with patient outcomes. Results: Forty-three patients were included. Sixteen (37%) patients had a Cancer of the Liver Italian Program (CLIP) score of 4, and 31 (72%) patients had chronic hepatitis B virus infection. The objective response rate was 9%, and the disease stabilization rate was 33%. The median progression-free survival was 1.9 months (95% CI 1.7-2.1 months), and the median OS was 4.6 months (95% CI 2.3-6.9 months). Treatment was generally tolerable. High baseline plasma levels of interleukin (IL)-6 and IL-8 were adversely correlated with patient survivals. Conclusions: The combination of thalidomide and tegafur/uracil was safe and demonstrated modest activity in patients with advanced HCC.

Original languageEnglish
Pages (from-to)59-66
Number of pages8
JournalOncology
Volume82
Issue number1
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Fingerprint

Thalidomide
Hepatocellular Carcinoma
Biomarkers
Safety
Drug Therapy
Tegafur
Uracil
Therapeutics
Angiogenesis Inducing Agents
Chronic Hepatitis B
Virus Diseases
Liver Neoplasms
Interleukin-8
Hepatitis B virus
Disease-Free Survival
Interleukin-6
Research Personnel
Survival

Keywords

  • Hepatocellular carcinoma
  • Interleukin-6
  • Interleukin-8
  • Metronomic chemotherapy
  • Thalidomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. / Shao, Yu Yun; Lin, Zhong Zhe; Hsu, Chiun; Lee, Kuan Der; Hsiao, Chi Huang; Lu, Yen Shen; Huang, Chien Chung; Shen, Yin Chun; Hsu, Chih Hung; Cheng, Ann Lii.

In: Oncology, Vol. 82, No. 1, 02.2012, p. 59-66.

Research output: Contribution to journalArticle

Shao, YY, Lin, ZZ, Hsu, C, Lee, KD, Hsiao, CH, Lu, YS, Huang, CC, Shen, YC, Hsu, CH & Cheng, AL 2012, 'Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma', Oncology, vol. 82, no. 1, pp. 59-66. https://doi.org/10.1159/000336126
Shao, Yu Yun ; Lin, Zhong Zhe ; Hsu, Chiun ; Lee, Kuan Der ; Hsiao, Chi Huang ; Lu, Yen Shen ; Huang, Chien Chung ; Shen, Yin Chun ; Hsu, Chih Hung ; Cheng, Ann Lii. / Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. In: Oncology. 2012 ; Vol. 82, No. 1. pp. 59-66.
@article{c73fe76c04a3437ab59f254dea22429a,
title = "Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma",
abstract = "Objectives: Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC). We initiated a phase II study to determine the safety and efficacy of adding metronomic chemotherapy to thalidomide as first-line therapy. Methods: This open- labeled, single-arm, multicentered, investigator-initiated study enrolled patients with treatment-na{\"i}ve advanced HCC not amenable to locoregional therapies. Treatment included oral thalidomide (100 mg twice daily) and tegafur/uracil [125 mg/m2 (based on tegafur) twice daily]. Tumor assessment was performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Pretreatment plasma levels of angiogenesis factors were correlated with patient outcomes. Results: Forty-three patients were included. Sixteen (37{\%}) patients had a Cancer of the Liver Italian Program (CLIP) score of 4, and 31 (72{\%}) patients had chronic hepatitis B virus infection. The objective response rate was 9{\%}, and the disease stabilization rate was 33{\%}. The median progression-free survival was 1.9 months (95{\%} CI 1.7-2.1 months), and the median OS was 4.6 months (95{\%} CI 2.3-6.9 months). Treatment was generally tolerable. High baseline plasma levels of interleukin (IL)-6 and IL-8 were adversely correlated with patient survivals. Conclusions: The combination of thalidomide and tegafur/uracil was safe and demonstrated modest activity in patients with advanced HCC.",
keywords = "Hepatocellular carcinoma, Interleukin-6, Interleukin-8, Metronomic chemotherapy, Thalidomide",
author = "Shao, {Yu Yun} and Lin, {Zhong Zhe} and Chiun Hsu and Lee, {Kuan Der} and Hsiao, {Chi Huang} and Lu, {Yen Shen} and Huang, {Chien Chung} and Shen, {Yin Chun} and Hsu, {Chih Hung} and Cheng, {Ann Lii}",
year = "2012",
month = "2",
doi = "10.1159/000336126",
language = "English",
volume = "82",
pages = "59--66",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma

AU - Shao, Yu Yun

AU - Lin, Zhong Zhe

AU - Hsu, Chiun

AU - Lee, Kuan Der

AU - Hsiao, Chi Huang

AU - Lu, Yen Shen

AU - Huang, Chien Chung

AU - Shen, Yin Chun

AU - Hsu, Chih Hung

AU - Cheng, Ann Lii

PY - 2012/2

Y1 - 2012/2

N2 - Objectives: Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC). We initiated a phase II study to determine the safety and efficacy of adding metronomic chemotherapy to thalidomide as first-line therapy. Methods: This open- labeled, single-arm, multicentered, investigator-initiated study enrolled patients with treatment-naïve advanced HCC not amenable to locoregional therapies. Treatment included oral thalidomide (100 mg twice daily) and tegafur/uracil [125 mg/m2 (based on tegafur) twice daily]. Tumor assessment was performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Pretreatment plasma levels of angiogenesis factors were correlated with patient outcomes. Results: Forty-three patients were included. Sixteen (37%) patients had a Cancer of the Liver Italian Program (CLIP) score of 4, and 31 (72%) patients had chronic hepatitis B virus infection. The objective response rate was 9%, and the disease stabilization rate was 33%. The median progression-free survival was 1.9 months (95% CI 1.7-2.1 months), and the median OS was 4.6 months (95% CI 2.3-6.9 months). Treatment was generally tolerable. High baseline plasma levels of interleukin (IL)-6 and IL-8 were adversely correlated with patient survivals. Conclusions: The combination of thalidomide and tegafur/uracil was safe and demonstrated modest activity in patients with advanced HCC.

AB - Objectives: Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC). We initiated a phase II study to determine the safety and efficacy of adding metronomic chemotherapy to thalidomide as first-line therapy. Methods: This open- labeled, single-arm, multicentered, investigator-initiated study enrolled patients with treatment-naïve advanced HCC not amenable to locoregional therapies. Treatment included oral thalidomide (100 mg twice daily) and tegafur/uracil [125 mg/m2 (based on tegafur) twice daily]. Tumor assessment was performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Pretreatment plasma levels of angiogenesis factors were correlated with patient outcomes. Results: Forty-three patients were included. Sixteen (37%) patients had a Cancer of the Liver Italian Program (CLIP) score of 4, and 31 (72%) patients had chronic hepatitis B virus infection. The objective response rate was 9%, and the disease stabilization rate was 33%. The median progression-free survival was 1.9 months (95% CI 1.7-2.1 months), and the median OS was 4.6 months (95% CI 2.3-6.9 months). Treatment was generally tolerable. High baseline plasma levels of interleukin (IL)-6 and IL-8 were adversely correlated with patient survivals. Conclusions: The combination of thalidomide and tegafur/uracil was safe and demonstrated modest activity in patients with advanced HCC.

KW - Hepatocellular carcinoma

KW - Interleukin-6

KW - Interleukin-8

KW - Metronomic chemotherapy

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84862824694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862824694&partnerID=8YFLogxK

U2 - 10.1159/000336126

DO - 10.1159/000336126

M3 - Article

C2 - 22310088

AN - SCOPUS:84862824694

VL - 82

SP - 59

EP - 66

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -